SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-016168
Filing Date
2020-06-29
Accepted
2020-06-29 18:27:22
Documents
42
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0320_actiniumpharma.htm 10-Q 530146
2 CERTIFICATION f10q0320ex31-1_actinium.htm EX-31.1 8475
3 CERTIFICATION f10q0320ex31-2_actinium.htm EX-31.2 8407
4 CERTIFICATION f10q0320ex32-1_actinium.htm EX-32.1 4268
5 CERTIFICATION f10q0320ex32-2_actinium.htm EX-32.2 4183
  Complete submission text file 0001213900-20-016168.txt   2180558

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20200331.xml EX-101.INS 260279
7 XBRL SCHEMA FILE atnm-20200331.xsd EX-101.SCH 33303
8 XBRL CALCULATION FILE atnm-20200331_cal.xml EX-101.CAL 34087
9 XBRL DEFINITION FILE atnm-20200331_def.xml EX-101.DEF 88302
10 XBRL LABEL FILE atnm-20200331_lab.xml EX-101.LAB 218589
11 XBRL PRESENTATION FILE atnm-20200331_pre.xml EX-101.PRE 157201
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 20998442
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences